Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 146 for

Edit search filters
  1. Study Of Vorasidenib (AG-881) In Participants With Residual Or Recurrent Grade 2 Glioma With An IDH1 Or IDH2 Mutation (INDIGO)

    Jacksonville, FL, Rochester, MN

  2. Pilot Study Of Care At Home For Monitoring Brain Tumor Patients

    Rochester, MN

  3. A Study Of The Drugs Selumetinib Vs. Carboplatin And Vincristine In Patients With Low-Grade Glioma

    Rochester, MN

  4. Testing The Addition Of An Anti-cancer Drug, Selinexor, To The Usual Chemotherapy Treatment (Temozolomide) For Brain Tumors That Have Returned After Previous Treatment

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. A Study Of The Drugs Selumetinib Versus Carboplatin/Vincristine In Patients With Neurofibromatosis And Low-Grade Glioma

    Rochester, MN

  6. Targeted Therapy Directed By Genetic Testing In Treating Pediatric Patients With Relapsed Or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, Or Histiocytic Disorder

    Rochester, MN

  7. Vorinostat, Temozolomide, or Bevacizumab in Combination with Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients with Newly Diagnosed High-Grade Glioma

    Rochester, MN

  8. Enhancing Facial Nerve Neuroprotection and Regeneration Through Omega-3 Supplementation Following Vestibular Schwannoma Resection

    Rochester, MN

  9. Intratumoral Extracellular Metabolic Impact Of DFMO And AMXT 1501 In Patients With Diffuse Or High Grade Glioma

    Rochester, MN

  10. Cerebrospinal Fluid Biomarkers For Brain Tumors

    Rochester, MN

.

Mayo Clinic Footer